Veterinary Diagnostics Company MI:RNA Raises $4 million Series A Funding

Investors in this round: NovaQuest, Kyoritsu Seiyaku, VANE. Animal Health Angels, Companion Fund I

Animal Health Angels are delighted to announce their most recent investment as a group into MI:RNA, the veterinary diagnostics company using cutting-edge technology and science to transform animal health diagnosis, as part of a $4 million in Series A funding round.

Aiming to change the future of animal health treatments through improved, earlier diagnostics, the capital will be used to continue global growth plans and revolutionise animal health testing, improving diagnosis and wellness among the pet, agriculture and equine sectors. MI:RNA’s vision is to change the approach to disease diagnosis to improve animals’ outcomes. The merits of MI:RNA technology are scientifically reviewed and proven, winning numerous grants and awards.

Funds have been raised from eight investors across three continents, including new investors,

NovaQuest (Lead Investor), Kyoritsu Seiyaku (Japanese pharma company), VANE (Angel Syndicate), Animal Health Angels, and Companion Fund I, LLC (VC). Existing investors adding to the series A round are Gabriel, Equity Gap and Scottish Enterprise.

Eve Hanks, CEO and founder, said: “Following on from our successful seed funding round from Gabriel Investments and Equity Gap, Series A is an important milestone in our global growth plans, as we seek to improve health outcomes for animals through earlier disease diagnosis using revolutionary biomarker technology and artificial intelligence. The geographical spread of this investment round reflects the global opportunity for MI:RNA to deploy our platform for better outcomes for pets.”     

Wendy Furness, Co-Founder and Director of Animal Health Angels, said “MI:RNA represents an exciting opportunity in an innovative animal health business with cutting edge science and technology at its fore. As a group of vets and animal health professionals our investors look to invest in brilliant businesses that make animal health care better and MI:RNI absolutely aligns with our strategy. This technology has huge potential to detect and stage ideas at an early stage and to positively impact healthcare in both companion and production animals. We were impressed by Eve and her team from the very onset; our angel group is committed to supporting the Investing in Women code and we had no hesitation in supporting MI:RNA as a female founded business”.

The investment will be used to continue to grow in partnership with key multinationals in animal health, with MI:RNA on the path to become a leading global tech company delivering impact for pets, farmers and the environment.


For media enquiries please contact Muckle Media for MI:RNA on 0131 2289713 or email mirna@mucklemedia.co.uk

About MI:RNA

MI:RNA Diagnostics have developed a novel early disease detection technology for the pet, agriculture and equine sectors veterinary market that uses microRNA biomarkers to accurately identify if disease is present, through blood sample analysis.

 About the Animal Health Angels network

The Animal Health Angels network is a pioneering initiative, led by team of experienced veterinary surgeons and accomplished animal health industry experts, that invest in brilliant businesses destined to make animal health care better. They seek to connect to visionary entrepreneurs with the resources and guidance necessary to develop innovative solutions that enhance the well-being of animals across species in the UK and Europe. Through mentorship, funding and networking opportunities Animal Health Angels aims to drive positive change in the animal health sector and promote sustainable practices in the field. Animal Heath Angels is a signatory to the Investing in Women Code. For more information, please visit www.animalhealthangels.com


Veterinary Diagnostics Company MI:RNA Raises $4 million Series A Funding

Veterinary Diagnostics Company MI:RNA Raises $4 million Series A Funding

By Animal Health Angels Animal Health Angels Profile 04 Jul 2024